Novo Nordisk shares rise after Wegovy recommended by Britain's drug price regulator
Story summaryNovo Nordisk rose as much as 4% after England's drug price regulator recommended the use of its best-selling drug Wegovy to prevent heart attacks and strokes.
Read at CNBCOpens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.